Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes
- PMID: 34648930
- PMCID: PMC8505019
- DOI: 10.1016/j.tmaid.2021.102171
Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes
Abstract
Background: With no vaccines or specific treatments, non-pharmaceutical interventions are the only tools for controlling the human-to-human transmission of the COVID-19 disease, which appeared in Wuhan, China last December and has spread globally since. Here we describe and compare the first-wave mitigation strategies and epidemiology of five Asia-Pacific countries that responded rapidly to the epidemic.
Methods: From January to April 2020, mitigation measures and epidemiological data for Singapore, South Korea, Japan, Taiwan, Hong Kong were screened from official local government websites and a review of investigational studies was conducted. Daily case reports and mitigation measures information were extracted. Epidemiological estimates were calculated and compared between countries.
Results: All five countries combined measures, focusing on contact tracing, testing, isolation efforts and healthcare management. Epidemiological data varied temporally and geographically: incubation period ranged 3.9-7.1 days, effective reproduction number at time t (Rt) ranged 0.48-1.5, with intensive care admissions 1-3% of hospitalised patients, and case fatality rates were 0.1-3%. Extrinsic estimates to the virus were lower than global estimates.
Conclusion: Implemented mitigation strategies in these countries allowed a rapid and successful control or delay of the first COVID-19 pandemic wave. These are valuable examples to inform subsequent waves.
Keywords: Asia; COVID-19; Epidemiology; First wave; Mitigation strategies.
Copyright © 2021. Published by Elsevier Ltd.
Conflict of interest statement
CEG, GN, RH are employees of Sanofi Pasteur, which is developing vaccines against COVID-19. LC, OV are employees of Corporate Value Associates. CS has no competing interest to declare. PV received grants from ANIOS, consulting fees from GSK, PFIZER ASTELLAS, Biosciences.
Figures
References
-
- Current World Population https://www.worldometers.info/world-population/ accessed.
-
- The World Bank World bank open data. https://data.worldbank.org/ accessed.
-
- World Health Organization Avian influenza A(H7N9) virus. https://www.who.int/influenza/human_animal_interface/influenza_h7n9/en/ accessed.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
